RESEARCH PAPER
Figure from article: Fosfomycin susceptibility...
 
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Antibiotic prophylaxis is one of the methods for preventing urinary tract infection (UTI) after urogynecological surgeries. Fosfomycin trometamol (FT) has emerged as a promising option in cases involving multidrug-resistant (MDR) pathogens in which previous antibiotics have failed. The aim of the study is to analyze the susceptibility to FT of common uropathogens, resistant to other antibiotics in patients with post-operative UTI.

Material and methods:
A retrospective study of susceptibility and resistance to commonly used antibiotics was performed by examining the results of urine analysis (n=173) of women with UTI after urogynaecological surgeries. The agar dilution method with glucose-6-phosphate for MIC determination were used for resistance and susceptibility testing in positive urine cultures (≥105 colony forming units (CFUs)/mL). Resistance to commonly used antibiotics was analyzed in comparison to resistance to FT.

Results:
In 173 results of urine analysis, 95.95% of the total isolates were found to be susceptible to FT. Among isolates resistant to amoxicillin/clavulanic acid, ampicillin, cephalexin, trimethoprim/sulfamethoxazole, ciprofloxacin, nitrofurantoin; respectively, 80.00%, 94.44%, 77.78%, 96.30%, 90.91%, and 84.38% were susceptible to FT.

Conclusions:
Peri-operative prophylaxis of UTI with FT is a promising alternative to classic antibiotics due to the high susceptibility of uropathogens, including MDR isolates. The decision about the prophylaxis method should be made based on the epidemiological updated recommendations. The study shows the need for ongoing observation of antibiotic resistance patterns in order to guide prophylaxis recommendations, especially in the era of MDR pathogens.
FUNDING
This research was funded by the Medical University of Lublin from the statutory funds DS321.
REFERENCES (26)
1.
World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Available at: https://www.who.int.
 
2.
Bradley MS, Cabrera C, Clark SG, et al. Sporadic compared to recurrent urinary tract infections: Considerations for urogynecologic patients. Neurourol Urodyn. 2020 Nov;39(8):2186–2191. doi:10.1002/nau.24471. Epub 2020 Aug 17. PMID: 32803912; PMCID: PMC7709465.
 
3.
Anger J, Lee U, Ackerman AL, et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol. 2019 Aug;202(2):282–289.
 
4.
Wu E, Kuehl TJ, Danford JM, et al. Postoperative prophylactic antibiotics for retropubic mid-urethral slings. Int Urogynecol J. 2022 Apr;33(4):897–902.
 
5.
Sanaee MS, Hutcheon JA, Larouche M, et al. Urinary tract infection prevention after midurethral slings in pelvic floor reconstructive surgery: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019;98:1514–1522.
 
6.
Mooren ES, Liefers WJ, de Leeuw JW. Cranberries after pelvic floor surgery for urinary tract infection prophylaxis: A randomized controlled trial. Neurourol Urodyn. 2020 Jun;39(5):1543–1549.
 
7.
Jung CE, Brubaker L. Postoperative urinary tract infection after urogynecologic surgery: timing and uropathogens. Int Urogynecol J. 2020 Aug;31(8):1621–1626.
 
8.
Aggarwal N, Leslie SW. Recurrent Urinary Tract Infections. 2025 Jan 20. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan;32491411.
 
9.
Ruiz Ramos J, Salavert Lletí M. Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens. Rev Esp Quimioter. 2019 May;32 Suppl 1(Suppl 1):45–54.
 
10.
Falagas ME, Athanasaki F, Voulgaris GL, et al. Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences. Int J Antimicrob Agents. 2019 Jan;53(1):22–28.
 
11.
Rossignol L, Vaux S, Maugatetal S. Incidenceofurinarytract infections and antibiotic resistance in the outpatient setting: a cross-sectional study. Infection. 2017;45(1):33–40.
 
12.
Thomas-White KJ, Gao X, Lin H, et al. Urinary microbes and postoperative urinary tract infection risk in urogynecologic surgical patients. Int Urogynecol J. 2018 Dec;29(12):1797–1805.
 
13.
Rechberger E, Rechberger T, Wawrysiuk S, et al. A Randomized Clinical Trial to Evaluate the Effect of Canephron N in Comparison to Ciprofloxacin in the Prevention of Postoperative Lower Urinary Tract Infections after Midurethral Sling Surgery. J Clin Med. 2020;9(11):3391.
 
14.
Thompson ND, Penna A, Eure TR, et al. Epidemiology of Antibiotic Use for Urinary Tract Infection in Nursing Home Residents. J Am Med Dir Assoc. 2020 Jan;21(1):91–96.
 
15.
US Food and Drug Administration: Drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections 2016. Available at: www.fda.gov/Drugs/DrugSafety/ucm500143.htm.
 
16.
NICE Nationale Institute for Health and Care Excellence: Surgical site infections: prevention and treatment. NICE Guidelines2019:www.nice.org.uk/guidence/ng125.
 
17.
Sanaee MS, Hutcheon JA, Larouche M, et al. Urinary tract infection prevention after midurethral slings in pelvic floor reconstructive surgery: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019 Dec;98(12):1514–1522.
 
18.
Svenningsen R, Kulseng-Hanssen S, et al. Is antibiotic prophylaxis necessary in mid-urethral sling surgery? Int Urogynecol J. 2021 Mar;32(3):629–635.
 
19.
Wawrysiuk S, Rechberger T, Kubik-Komar A, et al. Postoperative Prevention of Urinary Tract Infections in Patients after Urogynecological Surgeries—Nonantibiotic Herbal (Canephron) versus Antibiotic Prophylaxis (Fosfomycin Trometamol): A Parallel-Group, Randomized, Noninferiority Experimental Trial. Pathogens. 2023;12:27.
 
20.
Gupta K, Hooton TM, Naber NG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.
 
21.
Bonkat G, Bartoletti RR, Bruyère F, et al. EAU guidelines on urological infections European Association of Urology, Arnhem 2022; Available at:https://d56bochluxqnz.cloudfro... Clin Infect Dis. 2011;52(5):e103-e120.
 
22.
Berger AA, Tan-Kim J, Menefee SA. The impact of midurethral sling surgery on the development of urinary tract infections. Int Urogynecol. J. 2022;33:829–834.
 
23.
Pereira GMV, Brito LGO, Palma PCR. Urinary Tract Infection and Pelvic Organ Prolapse-an Association that Needs Further Clarification. Current Bladder Dysfunction Reports. Springer US; 2020.
 
24.
Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010 Jan;10(1):43–50.
 
25.
Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011 Nov;15(11):e732–9.
 
26.
Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from com- munity- acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012; 39:45–51.
 
eISSN:1898-2263
ISSN:1232-1966
Journals System - logo
Scroll to top